Tweet
Hum Vaccin Immunother
. 2024 Dec 31;20(1):2346388.
doi: 10.1080/21645515.2024.2346388. Epub 2024 Jun 26. The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines
Mine Durusu Tanriover 1 2 , Ozlem Altuntas Aydin 3 , Rahmet Guner 4 , Orhan Yildiz 5 , Ilhami Celik 6 , Sukran Kose 7 , Sila Akhan 8 , Emin Halis Akalin 9 , Aykut Ozdarendeli 10 11 , Serhat Unal 2 12 , Ihsan Ates 13 14 , Ates Kara 15 16 ; TURKOVAC Study Group
Collaborators, Affiliations
This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in Türkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vaccine local and systemic adverse events (AEs) comparing with CoronaVac. Of 1266 participants analyzed, 27.7% had a previous COVID-19 history. Local and systemic AEs were observed in 37.3% and 39% of the participants. The frequency of AEs was slightly higher in the first 30 minutes and 24 hours among participants with a COVID-19 history; none were severe. 1203 participants had a second dose vaccination, and 27.3% had a history of COVID-19. The frequencies of local and systemic AEs after the second dose were similar between those with and without a COVID-19 history. The TURKOVAC and CoronaVac showed similar frequencies of local and systemic AEs in the first 30 minutes after vaccination.
Keywords: COVID-19; CoronaVac; TURKOVAC; adverse events; inactive COVID-19 vaccine; previous infection; safety.
. 2024 Dec 31;20(1):2346388.
doi: 10.1080/21645515.2024.2346388. Epub 2024 Jun 26. The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines
Mine Durusu Tanriover 1 2 , Ozlem Altuntas Aydin 3 , Rahmet Guner 4 , Orhan Yildiz 5 , Ilhami Celik 6 , Sukran Kose 7 , Sila Akhan 8 , Emin Halis Akalin 9 , Aykut Ozdarendeli 10 11 , Serhat Unal 2 12 , Ihsan Ates 13 14 , Ates Kara 15 16 ; TURKOVAC Study Group
Collaborators, Affiliations
- PMID: 38924774
- DOI: 10.1080/21645515.2024.2346388
This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in Türkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vaccine local and systemic adverse events (AEs) comparing with CoronaVac. Of 1266 participants analyzed, 27.7% had a previous COVID-19 history. Local and systemic AEs were observed in 37.3% and 39% of the participants. The frequency of AEs was slightly higher in the first 30 minutes and 24 hours among participants with a COVID-19 history; none were severe. 1203 participants had a second dose vaccination, and 27.3% had a history of COVID-19. The frequencies of local and systemic AEs after the second dose were similar between those with and without a COVID-19 history. The TURKOVAC and CoronaVac showed similar frequencies of local and systemic AEs in the first 30 minutes after vaccination.
Keywords: COVID-19; CoronaVac; TURKOVAC; adverse events; inactive COVID-19 vaccine; previous infection; safety.